Drug General Information (ID: DDIS5P6V2W)
Drug Name			Vitamin E		Drug Info		Iloprost		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Vitamins				Antihypertensive Agents
Structure

Mechanism of Vitamin E-Iloprost Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Vitamin E				Iloprost
Mechanism		Risk of bleeding Anticoagulant effects				Risk of bleeding Antiplatelet effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Vitamin E and Iloprost

Recommended Action
Management		Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.

References
1	Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, et al "Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status." Am J Clin Nutr 80 (2004): 143-8. [PMID: 15213041]
2	Celestini A, Pulcinelli FM, Pignatelli P, et al. "Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets." Haematologica 87 (2002): 420-6. [PMID: 11940487]
3	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4	Corrigan JJ "The effect of vitamin E on warfarin-induced vitamin K deficiency." Ann N Y Acad Sci 393 (1982): 361-8. [PMID: 6959563]
5	Corrigan JJ, Ulfers LL "Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency." Am J Clin Nutr 34 (1981): 1701-5. [PMID: 7282596]
6	Freedman JE, Farhat JH, Loscalzo J, Keaney JF "Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C--dependent mechanism." Circulation 94 (1996): 2434-40. [PMID: 8921785]
7	Gonzalez-Correa JA, Arrebola MM, Guerrero A, et al. "Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood." Platelets 16(3-4) (2005): 171-9. [PMID: 16011961]
8	Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
9	Helson L "The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors." Thromb Res 35 (1984): 11-8. [PMID: 6474408]
10	Jandak J, Steiner M, Richardson PD "Alpha-tocopherol, an effective inhibitor of platelet adhesion." Blood 73 (1989): 141-9. [PMID: 2910355]
11	Kakishita E, Suehiro A, Oura Y, Nagai K "Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood." Thromb Res 60 (1990): 489-99. [PMID: 2082481]
12	Kim JM, White RH "Effect of vitamin E on the anticoagulant response to warfarin." Am J Cardiol 77 (1996): 545-6. [PMID: 8629604]
13	Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, Saldeen T "Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms." Am J Clin Nutr 77 (2003): 700-6. [PMID: 12600864]
14	Mardla V, Kobzar G, Samel N "Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin." Platelets 15 (2004): 319-24. [PMID: 15370103]
15	Megavitamin E supplementation and vitamin K-dependent carboxylation. Nutr Rev 41 (1983): 268-70. [PMID: 6358960]
16	Murohara T, Ikeda H, Otsuka Y, Aoki M, Takajo Y, et al "Inhibition of platelet adherence to Mononuclear cells by alpha-tocopherol: role of P-selection." Circulation 110 (2004): 141-8. [PMID: 15197142]
17	Schrogie JJ "Coagulopathy and fat-soluble vitamins." JAMA 232 (1975): 19. [PMID: 1172961]
18	Stampfer MJ, Jakubowski JA, Faigel D, Vaillancourt R, Deykin D "Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels." Am J Clin Nutr 47 (1988): 700-6. [PMID: 3128100]
19	Vitamin K, vitamin E and the coumarin drugs. Nutr Rev 40 (1982): 180-2. [PMID: 7121898]
20	Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C "Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis." Pharmacotherapy 27 (2007): 1237-47. [PMID: 17723077]